作　　者： (孟菁菁）; (谷少杰）; (张琳）; (贾建民）;

机构地区： 郑州大学第五附属医院,450000

出　　处： 《实用癌症杂志》 2017年第9期1438-1440,共3页

摘　　要： 目的探讨晚期非小细胞肺癌患者血清CA125、CEA、IL-10水平在预后中的价值。方法采用ELISA法检测不同分期NSCLC患者治疗前后CA125、CEA、IL-10的水平;观察对比化疗前后不同分期的NSCLC患者CA125、CEA、IL-10的表达水平;评价化疗后NSCLC患者的疗效及生存期。结果化疗前Ⅳ期患者CA125、CEA、IL-10水平高于Ⅲ期患者;PR患者血清CA125、CEA、IL-10水平治疗后明显降低,SD患者CA125、CEA、IL-10水平治疗前后无显著变化,PD患者CA125、CEA、IL-10水平治疗后均显著升高;PR患者平均生存期显著长于SD患者,SD患者平均生存期显著长于PD患者。结论血清CA125、CEA、IL-10是评估晚期非小细胞肺癌患者预后有价值的指标。 Objective To investigate the prognostic value of serum CA125,CEA and IL-10 in advanced non-small cell lung cancer（ NSCLC）. Methods The levels of CA125,CEA and IL-10 were measured before and after treatment in patients with NSCLC. The levels of these indicators in NSCLC patients before and after chemotherapy were observed. The therapeutic effect and survival period of NSCLC patients after chemotherapy was evaluated. Results The levels of CA125,CEA and IL-10 in stage Ⅳpatients were higher than those of stage Ⅲ patients before chemotherapy; PR patients serum CA125,CEA,IL-10 levels were significantly reduced after treatment,there were no significant changes in CA125,CEA and IL-10 levels in SD patients before and after treatment,PD patients serum CA125,CEA,IL-10 levels significantly increased after treatment; The average survival time of PR patients was significantly longer than that of SD patients. The mean survival time of SD patients was significantly longer than that of patients with PD. Conclusion Serum CA125,CEA and IL-10 levels are valuable indicators to evaluate the prognosis for NSCLC.

关 键 词： 非小细胞肺癌 糖类抗原 癌胚抗原 白介素 预后